FIELD: medicine.
SUBSTANCE: it is offered amorphous dehydrated calcium metasilicate, concerning the sizes (average big axial diameter/average small axial diameter) from approximately 1:1 to approximately 2.5:1 and absorption of oil from approximately 20 ml/100 g to approximately 220 ml/100 g, and also a way of its obtaining. Amorphous dehydrated calcium metasilicate apply to obtaining of the solid pharmaceutical form for oral introduction.
EFFECT: obtaining quickly disintegrated solid pharmaceutical form.
19 cl, 13 tbl, 2 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2005 |
|
RU2384328C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2009 |
|
RU2438661C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PRODRUG OF HCV POLYMERASE INHIBITOR | 2010 |
|
RU2489153C2 |
| ORAL ANTITUMOUR DRUGS AND METHOD FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2639479C1 |
| COMPOSITION OF SOLID QUICK-DISINTEGRATING TABLET | 2008 |
|
RU2472493C2 |
| CINACALCET HYDROCHLORIDE TABLET CORE | 2019 |
|
RU2750761C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| TABLET COMPOSITION COMPRISING CINACALCET HYDROCHLORIDE | 2013 |
|
RU2662562C2 |
